arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Cadrenal Therapeutics, Inc.

CVKD

$1.31 ▲ +0.20 (+17.49%) at close

4 Visible periods

20 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Cadrenal Therapeutics, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $2.6M

Dividend Yield 1259.54%

Revenue Growth —

Op. Margin —

ROIC -388.3% ↘

FCF / Share $-6.32 ↘

Trailing P/E —

Price / Book 1.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-13.24M

↓ -24.3% —

FCF / Share Free cash flow per share

$-6.32

↓ -4.7% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -388.3% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.95x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$16.50 Latest / share

+0.0% YoY

+0.0% 2-yr CAGR

FY 2022

FY 2023

$16.50

FY 2024

$16.50

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	23.9% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	6.0% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-992.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	-24.3% Weak ↑ Weak Improving Year-over-year change in net income	-27.5% Weak Weak Year-over-year change in net income	-24.5% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	-4.7% Weak ↑ Weak Improving Year-over-year change in free cash flow	-53.7% Weak Weak Year-over-year change in free cash flow	-2468.1% Weak Weak Year-over-year change in free cash flow	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.42x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.18x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-388.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-116.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-78.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	38.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-311.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-108.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-89.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-347.2% Weak Weak Operating profit relative to total assets Optimal: > 10%
Return on Common Equity (%) (%)	—	-143.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1054%)	-108.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-824%)	121.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+706%)

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-4.01M	$-10.00M	—	$-32.59K

📊 What does each share earn? 7 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-6.64	$-8.73	$-9.29	$-0.85
Free Cash Flow per Share (USD)	$-6.32	$-6.04	$-3.93	$-0.15
Dividend per Share (USD)	$16.50	$16.50	—	—
Book Value per Share (USD)	$1.17	$4.17	$8.86	$-0.68
Tangible Book Value per Share (USD)	$1.17	$4.17	$8.86	$-0.68
Basic Weighted Avg Shares (shares)	1.99M	1.22M	899,465	7.89M
Dividend Payout Ratio (%)	-248.5% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	-189.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$2.73M	$7.43M	$7.67M	$-606.88K
Total Equity (USD)	$2.74M	$7.44M	$7.69M	$-5.55M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	$6.87K	$1.88K	$1.98K	$1.27K
Net Income, GAAP (USD)	$-13.24M	$-10.65M	$-8.36M	$-6.71M
Operating Cash Flow (USD)	$-12.60M	$-7.36M	$-3.53M	$-1.20M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 18 quarters

Cadrenal Therapeutics, Inc.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare CVKD with peers